RxDoctor Payments Data

Ata Salek, MD

Family Medicine · Houston, TXNPI 1063567840

Payments from drug & device makers

$11,118in general payments, 2019–2025

Across 542 payments — averaging $20.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Novo Nordisk$1K
  • AbbVie$1K
  • GSK$1K
  • Bayer$802
  • Amgen$629
  • plus $5K from 39 others

What the payments were for

  • Food & beverage$10,576100%
  • Education$420%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,118 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$76,230
Medicare patients
282
Services billed
951

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin145$196,572
OzempicSemaglutide129$183,256
FarxigaDapagliflozin Propanediol151$160,409
Trelegy ElliptaFluticasone/Umeclidin/Vilanter103$96,829
EliquisApixaban73$85,574
MounjaroTirzepatide55$77,633
JanuviaSitagliptin Phosphate38$46,508
TrulicityDulaglutide32$43,602
MyrbetriqMirabegron41$38,543
LinzessLinaclotide32$37,421
XareltoRivaroxaban23$29,370
TradjentaLinagliptin14$17,799
GemtesaVibegron18$17,654
Rosuvastatin Calcium485$8,482
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$7,896

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$510$214,371159 claims
Novo NordiskOzempic$1,091$183,256129 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,638$168,306163 claims
Lilly USA, LLCMounjaro, Trulicity$409$121,23587 claims
GSKTrelegy Ellipta$1,081$96,829103 claims
PfizerEliquis$490$85,57473 claims
MerckJanuvia$324$46,50838 claims
AbbVieLinzess, Synthroid$1,081$43,72085 claims
Astellas Pharma US IncMyrbetriq$118$38,54341 claims
Johnson & JohnsonXarelto$279$29,37023 claims
Sumitomo Pharma America, Inc.Gemtesa$93$17,65418 claims
Sanofi-aventis U.S. LLCLantus$121$1,99612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →